Yesterday, Merck (NYSE:MRK) licensed the rights to an over-the-counter (OTC) version of its cholesterol-lowering drug MEVACOR to GlaxoSmithKline (NYSE:GSK), but the deal is far from done. Merck has ...
The FDA needs to see additional data from Merck before approving an OTC version of the drugmaker’s cholesterol-lowering drug Mevacor (lovastatin). The agency requested the data along with revised ...
Sept. 28, 2005 ( updated Oct. 6, 2005) -- The U.S. Food and Drug Administration (FDA) approved safety labeling revisions in June to advise that doxercalciferol dose reductions are recommended in ...
An FDA advisory panel has rejected Merck’s bid to sell the cholesterol-lowering drug Mevacor without a prescription. The panel voted 10-2 against recommending OTC sales of the drug. The rejection ...
Merck's latest attempt to sell its oldest cholesterol-lowering drug, Mevacor, over the counter without a prescription is once again being questioned at the Food and Drug Administration. In preparation ...
Federal health advisers recommended against over-the-counter sales of a cholesterol drug, saying that patients need medical guidance in treating a condition that has no symptoms and may require drugs ...
As part of their new joint venture, Johnson & Johnson and Merck want to take their cholesterol-lowering drug Mevacor (lovastatin) from prescription to over-the-counter status, according to company ...
U.S. government advisers rejected Merck & Co.'s latest bid for over-the-counter sales of Mevacor, the granddaddy of the famed cholesterol-lowering drugs. They said it is too complicated for consumers ...
GlaxoSmithKline has reached an agreement with fellow drugs giant Merck & Co to sell an over-the-counter version of the latter’s old cholesterol-lowering product Mevacor which has still not been ...
As expected, regulators in the USA have rejected Merck & Co’s bid to get the green light for an over-the-counter version of its cholesterol-lowerer Mevacor. As expected, regulators in the USA have ...
Merck & Co. on Friday said the Food and Drug Administration rejected its application to market an over-the-counter cholesterol drug. Subscribe to read this story ad-free Get unlimited access to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results